SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as escalating geopolitical tensions involving the US, Israel, and Iran spark intense community debate, with many divided between anticipating a significant market correction and a "buy the dip" mentality, while concerns over rising oil prices and market manipulation remain key talking points.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as escalating US-Iran conflict, including military engagements and attacks on critical oil infrastructure like the Ras Tanura refinery, fuels widespread market uncertainty. The community remains sharply divided between those predicting a major market downturn and dip-buyers expecting a rebound from geopolitical volatility.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating Middle East tensions, following drone strikes on Saudi oil facilities and effective restrictions in the Strait of Hormuz, are sending crude prices soaring, leading the community to anticipate a significant short squeeze and parabolic rally for low-float energy play Indonesia Energy Corp.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is surging amid escalating geopolitical tensions in the Middle East, with reports of drone strikes on Saudi Arabian oil facilities and concerns over the Strait of Hormuz driving up oil prices. The community is focused on the company's low float and high short interest, anticipating a significant short squeeze within the red-hot energy sector.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

Escalating Middle East tensions are driving discussion around USO, fueled by US-Israeli strikes, Iran's retaliation, and significant shipping disruptions in the Strait of Hormuz. The community is actively debating whether these events signal a sustained crude oil rally or if the initial price spike will quickly dissipate.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The DIA ETF is trending due to rapidly escalating geopolitical tensions in the Middle East, with community sentiment sharply divided between anticipating significant market corrections and viewing the situation as a "buy the dip" opportunity, alongside fresh tariff developments and hotter inflation data contributing to broad market volatility.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing a sharp sell-off, driven by broader market jitters over geopolitical events and concerns impacting the financial sector, leading to an outsized decline compared to peers. The community is actively discussing this downturn, with many advocating to "buy the dip" citing strong fundamentals and potential S&P inclusion, while others express frustration over perceived manipulation and warn of further price deterioration.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is rallying on an earnings beat and highly optimistic revenue guidance, fueled by surging demand for its 800G optical transceivers critical for AI data centers. The community is sharply divided, with bulls highlighting its essential role in AI infrastructure and aggressive growth outlook, while skeptics point to historical over-guidance and concerns over a recent stock offering.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending amid escalating geopolitical tensions impacting global LNG supply routes, sparking calls for a massive short squeeze and high anticipation for its upcoming earnings. The community is highlighting the company's rapid capacity expansion and strategic positioning as an undervalued leader poised for substantial growth in a tight energy market.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

Zymeworks is trending following overwhelmingly positive Phase 3 results for its lead therapeutic, Ziihera, in gastroesophageal adenocarcinoma, suggesting a new standard of care, compounded by its recent FDA approval for biliary tract cancer. This success has ignited community discussions about substantial milestone payments, upcoming royalties, and strong speculation regarding a potential acquisition by partner Jazz Pharmaceuticals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of "Hold" by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six research firms that are presently covering the firm, Marketbeat Ratings...

BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

BTIG Research reaffirmed a "buy" rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Wednesday...

NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Decrease in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 3,527,843 shares, an...

New Strong Sell Stocks for January 27th

DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company...

NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

Equity

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.


D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a "buy" rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Monday...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRXP News

NRXPNRX Pharmaceuticals Inc